Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04498117
Title Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors OncoQuest Pharmaceuticals Inc.

endometrioid ovary carcinoma

fallopian tube adenocarcinoma

ovarian clear cell adenocarcinoma

peritoneal carcinoma

ovary adenocarcinoma

ovarian carcinoma

ovary serous adenocarcinoma


Carboplatin + Oregovomab + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | BEL

No variant requirements are available.